MicroPort EP(SH:688351) HTSC·2025-10-28 05:42Investment Rating - The investment rating for the company is maintained at "Buy" with a target price of 29.79 RMB [7]. Core Insights - The company reported a revenue of 336 million RMB for the first three quarters of 2025, representing a year-over-year increase of 15.7%. The net profit attributable to the parent company was 41.92 million RMB, up 0.5% year-over-year. In Q3 2025, revenue reached 113 million RMB, showing a year-over-year growth of 21.8% but a quarter-over-quarter decline of 5.9%. The decrease in net profit in Q3 2025 was primarily due to a significant reduction in other income, mainly government subsidies [1][2]. - The gross margin for the first three quarters of 2025 was 59.1%, an increase of 0.3 percentage points year-over-year, driven by a higher proportion of revenue from high-end products. The company is actively enhancing its commercialization capabilities while improving R&D efficiency [2]. - The overseas revenue is expected to continue its rapid growth due to improved commercialization capabilities and the approval of high-end products for CE certification, while domestic revenue is anticipated to stabilize as external industry factors are resolved [3][4]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 336 million RMB, with a year-over-year growth of 15.7%. The net profit attributable to the parent company was 41.92 million RMB, reflecting a slight increase of 0.5% year-over-year. In Q3 2025, revenue was 113 million RMB, marking a year-over-year increase of 21.8% but a quarter-over-quarter decrease of 5.9% [1]. - The gross margin for the first three quarters of 2025 was 59.1%, up 0.3 percentage points year-over-year, supported by a growing share of high-end product sales [2]. Product and Market Development - The company is seeing strong growth in high-end catheter products, with over 5,000 procedures completed for its pressure ablation catheter by Q3 2025. The overall revenue from this segment is expected to maintain rapid growth in 2025 [4]. - The company’s overseas revenue is projected to grow significantly due to enhanced commercialization efforts and the introduction of high-end products in new markets. Domestic revenue is expected to recover as external factors affecting the industry are alleviated [3]. Profitability and Valuation - The earnings per share (EPS) estimates for 2025-2027 have been adjusted to 0.14, 0.19, and 0.29 RMB, respectively, reflecting a downward revision of 22%, 26%, and 16% compared to previous estimates. The target price is set at 29.79 RMB, down from 31.18 RMB [5][17].